Navigation Links
Elekta Showcases Stereotactic Systems for Cancer Care at Astro 2007
Date:10/30/2007

LOS ANGELES, Oct. 30 /PRNewswire/ -- Elekta, a pioneer in the field of stereotactic radiosurgery, currently is showcasing the broadest portfolio of stereotactic technology in the industry at the 49th Annual Meeting of The American Society for Therapeutic Radiology and Oncology (ASTRO). Held October 28-November 1 at the Los Angeles Convention Center, ASTRO is the perfect forum for Elekta to showcase its latest products covering the full spectrum of stereotactic systems and solutions for planning, immobilization, treatment and post-processing.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020318/ELEKTALOGO )

"No other vendor has the breadth of solutions that Elekta offers its users," says Tomas Puusepp, Elekta President and CEO. "We provide innovations through the continuum of care that help fight serious disease and improve quality of life for patients."

Of the many programs that have acquired or plan to acquire a new linear accelerator within the next few years, the majority are adding radiosurgery capabilities. With its broad portfolio of solutions, Elekta is uniquely positioned to offer cancer programs the solutions they deem best for delivering radiosurgery.

Leksell Gamma Knife(R) Perfexion(TM) offers state-of-the-art radiosurgery with expanded treatment reach

The newest generation Leksell Gamma Knife(R) is Leksell Gamma Knife(R) Perfexion(TM). Leksell Gamma Knife is the only radiation therapy device cleared by the FDA for the treatment of brain metastases. Brain metastases, tumors originating from cancer in other parts of the body, have been increasing in incidence worldwide, and traditional treatments for these tumors often involve a long period of recovery, as well as side effects like nausea, vomiting and hair loss. Stereotactic radiosurgery with Leksell Gamma Knife Perfexion offers dramatic improvements in quality of life for brain metastases patients, with single-session treatments, faster recovery time and virtually no side effects.

For clinicians, Leksell Gamma Knife Perfexion offers absolute protocol reproducibility, allowing access to extensive Leksell Gamma Knife clinical experience from around the world. In addition, it gives virtually unlimited dose sculpting ability for sub-millimeter accuracy in targeting tumors of any shape, and expands treatment reach to a wider range of anatomical structure, enabling clinicians to treat more patients.

The new Leksell GammaPlan(R) PFX(TM) treatment planning software, now running on a PC-based platform, is as sophisticated as the system it controls. Providing enhanced, user-friendly management of Leksell Gamma Knife Perfexion technology, Leksell GammaPlan PFX gives superior dosimetry performance and excellent radiation protection for both the radiosurgery team and their patients.

Elekta Axesse(TM) provides excellence in SRS and SRT

In addition to innovative cranial radiosurgery solutions, Elekta is displaying Elekta Axesse(TM), a comprehensive and integrated full-body solution for performing both stereotactic radiosurgery (SRS) and stereotactic radiation therapy (SRT). Elekta Axesse combines true three-dimensional image guidance at the time of treatment with highly conformal beam shaping and robotically controlled 6D sub-millimeter patient positioning to deliver fast, efficient and accurate treatment. All treatment processes from planning to delivery are controlled from a single workstation to streamline workflow.

Elekta Synergy(R) is the Multi-Functional IGRT solution

Elekta Synergy(R) with X-ray Volume Imaging (XVI) enables clinicians to visualize internal structures, including soft tissues, in three dimensions at the time of treatment and in the same frame of reference. This innovative feature minimizes geometric uncertainties from organ motion and deformation as well as slight differences in patient set-up. Elekta Synergy inspires clinical confidence to undertake advanced radiation therapy techniques such as Intensity Modulated Arc Therapy (IMRT) and Image Guided Radiation Therapy (IGRT).

Upgrades for even more efficient stereotactic workflow with Elekta Synergy will be displayed at ASTRO. Medical Intelligence, an Elekta company, will display the non-invasive HeadFIX(R) and BodyFIX(R) patient-specific immobilization devices, which are vacuum-activated for highly accurate and reproducible positioning and immobilization. Elekta is showing three new micro multileaf collimators (MLCs), the most versatile technology available for SRS and SRT. All three micro MLCs - the 3mm, the 5mm and the 7mm leaf width - have improved dose shaping abilities for minimal risk to critical organs.

Illustrious history, solid future in stereotaxy

"Elekta's stereotactic products demonstrate its commitment to technological innovation and advances in stereotaxy," says Puusepp. Elekta was founded by the late professor Lars Leksell, a pioneer in minimally invasive surgery and inventor of the Leksell Stereotactic System(R) in 1948 and Leksell Gamma Knife in 1968. Since, Elekta has continued to set new standards in accuracy and therapeutic efficacy in both stereotactic radiation therapy and stereotactic radiosurgery.

"As Elekta develops high quality cost-effective solutions, cancer centers around the world are taking a major interest in adding whole-body radiosurgery to their radiation therapy capabilities," says Puusepp.

About Elekta

Elekta is an international medical technology group, providing oncologists, radiation therapists, neurosurgeons and many other medical specialists with state of the art tools to fight serious disease.

Elekta provides advanced clinical solutions, comprehensive management and information systems as well as services for improved cancer care and management of brain disorders.

Elekta's systems and solutions are used in over 4,500 hospitals around the world. Clinical and information management solutions include, among others, Leksell Gamma Knife(R) for non-invasive treatment of brain disorders, Elekta Axesse(TM) and Elekta Synergy(R) for stereotactic and image guided radiation therapy and radiosurgery as well as the MOSAIQ(TM) suite of software for image-enabled EMR and efficient management of clinical and patient data.

With more than 2,000 employees globally, the corporate headquarter is located in Stockholm, Sweden and the company is listed on the Nordic Exchange under the ticker EKTAb. More information about Elekta can be found at http://www.elekta.com.


'/>"/>
SOURCE Elekta, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Life-sciences conference showcases capital ideas of Wisconsin
2. Modine showcases CO2 cooled Jeep
3. Assess the In Vivo Activation of Signal Transduction Pathways with PathDetect Reporting Systems
4. prostar RT-PCR Systems for Robust High-Fidelity RNA Amplification
5. Performance Comparisons of Commercial RT-PCR Systems
6. Signal Transduction Reporting Systems Using Cis-Acting Enhancer Elements
7. In Vivo Signal Transduction Pathway Reporting Systems
8. Improved Vectors for PathDetect Trans-Reporting Systems
9. Genetic Reporter Systems
10. Genetic Reporter Systems
11. Matched siRNAs and Assays: Ambion + Applied Biosystems = RNAi Success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... China , Feb. 4, 2016 Beike ... and various medical institutions attended a ceremony in late ... integrative, personalized cell therapy in 2016. ... "Shenzhen Clinical Translation Platform for Personalized Cell Therapy" was ... Regional Cell Production Center, both subsidiaries of Beike Biotechnology ...
(Date:2/4/2016)... and MENLO PARK, Calif. , Feb. 4, ... and the "Company"), a biopharmaceutical company focused on the development ... will present at the 18 th Annual BIO ... at 10:00 a.m. EST in New York, NY ... and CEO, will provide an update on the ongoing clinical ...
(Date:2/4/2016)... Feb. 4, 2016 ContraVir Pharmaceuticals, Inc. (NASDAQ: ... development and commercialization of targeted antiviral therapies, announced today ... Conference 2016, to be held February 8-9, 2016, at ... 2016 Disruptive Growth & Healthcare Conference, taking place in ... 2016. James Sapirstein , Chief Executive Officer ...
(Date:2/4/2016)... BEIJING , Feb. 4, 2016 Sinovac ... ), a leading provider of biopharmaceutical products in ... committee of its board of directors received on February ... 3, 2016, from a consortium comprised of PKU V-Ming ... Sinobioway Biomedicine Co., Ltd., CICC Qianhai Development ( ...
Breaking Biology Technology:
(Date:2/2/2016)... Calif. , Feb. 2, 2016  Based ... market, Frost & Sullivan recognizes US-based Intelligent Retinal ... Frost & Sullivan Award for New Product Innovation. ... in North America , is ... the rapidly growing diabetic retinopathy market. The IRIS ...
(Date:1/28/2016)... Jan. 28, 2016 Synaptics (NASDAQ: SYNA ), a ... its second quarter ended December 31, 2015. ... of fiscal 2016 increased 2 percent compared to the comparable quarter ... of fiscal 2016 was $35.0 million, or $0.93 per diluted share. ... income for the first quarter of fiscal 2016 grew 9 percent ...
(Date:1/22/2016)... DUBLIN , January 22, 2016 ... has announced the addition of the  ... to their offering. --> ... of the  "Global Behavioral Biometric Market ... --> Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ...
Breaking Biology News(10 mins):